TransMedics Group (NASDAQ:TMDX) Stock Rating Lowered by Wall Street Zen

TransMedics Group (NASDAQ:TMDX) was downgraded by research analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued on Saturday.

Several other research firms also recently weighed in on TMDX. Weiss Ratings reissued a “hold (c)” rating on shares of TransMedics Group in a research report on Wednesday, October 8th. Canaccord Genuity Group boosted their price objective on TransMedics Group from $147.00 to $148.00 and gave the company a “buy” rating in a report on Wednesday, December 17th. Piper Sandler restated an “overweight” rating on shares of TransMedics Group in a research note on Monday, December 22nd. Morgan Stanley lifted their target price on TransMedics Group from $123.00 to $135.00 and gave the stock an “equal weight” rating in a research report on Tuesday, December 2nd. Finally, Jefferies Financial Group assumed coverage on TransMedics Group in a research report on Monday, October 13th. They set a “buy” rating and a $145.00 price target on the stock. Six analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $144.25.

TransMedics Group Stock Performance

Shares of TMDX opened at $133.98 on Friday. The firm has a market cap of $4.58 billion, a price-to-earnings ratio of 54.24 and a beta of 2.03. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43. The business’s 50 day moving average is $134.30 and its two-hundred day moving average is $123.60. TransMedics Group has a 52-week low of $62.07 and a 52-week high of $156.00.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a net margin of 16.20% and a return on equity of 31.42%. The business had revenue of $143.82 million during the quarter, compared to analyst estimates of $145.33 million. During the same quarter in the previous year, the firm earned $0.12 earnings per share. The business’s revenue was up 32.2% compared to the same quarter last year. Analysts forecast that TransMedics Group will post 1 EPS for the current fiscal year.

Insider Buying and Selling at TransMedics Group

In other news, Director David Weill sold 5,000 shares of the business’s stock in a transaction on Wednesday, December 3rd. The shares were sold at an average price of $138.64, for a total transaction of $693,200.00. Following the completion of the transaction, the director owned 12,134 shares of the company’s stock, valued at approximately $1,682,257.76. The trade was a 29.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Gerardo Hernandez sold 920 shares of the company’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $139.62, for a total transaction of $128,450.40. Following the transaction, the chief financial officer owned 15,064 shares of the company’s stock, valued at $2,103,235.68. This represents a 5.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 8,920 shares of company stock worth $1,257,310. 7.00% of the stock is owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Hedge funds and other institutional investors have recently made changes to their positions in the business. Royal Bank of Canada increased its position in TransMedics Group by 47.9% in the 1st quarter. Royal Bank of Canada now owns 26,582 shares of the company’s stock valued at $1,788,000 after acquiring an additional 8,604 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of TransMedics Group by 4.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 19,525 shares of the company’s stock worth $1,314,000 after purchasing an additional 868 shares in the last quarter. Goldman Sachs Group Inc. grew its stake in shares of TransMedics Group by 20.6% in the first quarter. Goldman Sachs Group Inc. now owns 507,510 shares of the company’s stock worth $34,145,000 after purchasing an additional 86,721 shares in the last quarter. Wealth Enhancement Advisory Services LLC acquired a new position in shares of TransMedics Group during the second quarter valued at $224,000. Finally, KLP Kapitalforvaltning AS raised its stake in shares of TransMedics Group by 3.1% during the second quarter. KLP Kapitalforvaltning AS now owns 6,600 shares of the company’s stock valued at $884,000 after purchasing an additional 200 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors and hedge funds.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.